David A. Urbanek - Mar 1, 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Signature
/s/ Catherine S. Powell, as Attorney-in-Fact for David A. Urbanek
Stock symbol
ELAN
Transactions as of
Mar 1, 2023
Transactions value $
-$43,593
Form type
4
Date filed
3/3/2023, 08:08 PM
Previous filing
Mar 3, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELAN Common Stock Tax liability -$32.9K -2.92K -3.16% $11.26 89.4K Mar 1, 2023 Direct F1
transaction ELAN Common Stock Award $0 +26.6K +29.72% $0.00 116K Mar 1, 2023 Direct F2
transaction ELAN Common Stock Tax liability -$10.7K -970 -0.84% $11.01 114K Mar 2, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Employee Stock Option (right to buy) Award $0 +60.7K $0.00 60.7K Mar 1, 2023 Common Stock 60.7K $11.26 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan.
F2 Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2023, one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.
F3 Balance reflects 659 fewer shares due to an error in the number of shares previously reported as forfeited in a prior Form 4.
F4 Grant of stock options vesting as follows: one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.

Remarks:

Executive Vice President, Manufacturing and Quality